Eddie Sullivan, SAB Biotherapeutics president and CEO

South Dako­ta-based Covid-19 trans­genic cow an­ti­body start­up claims its first PhI­II win

SAB Bio­ther­a­peu­tics, known for col­lect­ing and dis­till­ing an­ti­bod­ies from cows with hu­man­ized im­mune sys­tems, on Wednes­day said a Phase III tri­al it ran for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.